C.D.C. advisers will discuss whether to recommend Pfizer boosters for children 5 to 11.

Scientific advisers to the Facilities for Illness Management and Prevention will meet on Thursday to debate whether or not to advocate a 3rd dose of the Pfizer-BioNTech vaccine to kids ages 5 to 11.

The Meals and Drug Administration approved the booster shot for this age group on Tuesday. The C.D.C.’s advisers are additionally anticipated to endorse the photographs. Dr. Rochelle Walensky, the company’s director, is anticipated to log off shortly on the advice.

The additional dose might enhance immunity to the present Omicron variants in these kids. Research have proven that two doses of the vaccine supply nearly no barrier towards an infection with the Omicron variant in kids ages 5 to 11, though safety towards extreme illness stays sturdy.

In adolescents ages 12 to 17, two doses supplied little safety even towards hospitalization, however a booster shot considerably improved immunity.

Pfizer and BioNTech reported on Tuesday that in kids ages 5 to 11, a 3rd dose generated antibodies towards each the Omicron variant and the unique model of the coronavirus. In a medical trial, the kids acquired 10 micrograms of vaccine — one-third of the dose given to adolescents and adults — in every shot.

As with the primary two doses, the booster shot appeared secure, the businesses reported. Essentially the most generally reported unintended effects have been ache, redness and swelling on the injection website, in addition to aches, chills and fever.

Fewer than one-third of 5- to 11-year-olds in america have acquired two doses. Many dad and mom have hesitated to immunize their kids, partly as a result of they’re at a lot decrease danger of extreme illness than adults.

However report numbers of kids have been hospitalized through the Omicron surge this winter. And a few research counsel that even kids who’ve a gentle sickness might expertise signs for months.